anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The proposed study will examine physiologic responses to acute psychological challenge in the laboratory among healthy adults. It is widely accepted that there is an increase in circulating markers of inflammation following a single bout of laboratory stress. This increase in systemic inflammation is believed to contribute to the damaging health effect of psychological stress. However, to date, the biological mechanisms by which psychological stress is transduced into inflammation are unclear. The investigators' preliminary evidence suggests that mitochondrion may play a role, with stress-induced increases in circulating levels of mitochondria- derived signaling molecules that are known to modulate immune cell function and the production of pro-inflammatory cytokines.

To test this possibility, the investigators plan to conduct a crossover experimental trial examining physiological responses to an evaluative speech task under laboratory conditions. The investigators have previously used this task to induce physiological arousal. The investigators plan to recruit 60 non-smoking volunteers (50% female, aged 20-50 years) and test these participants on two occasions separated by at least a month. On one occasion the participants will be exposed to the speech task. On the other occasion, the participants will rest quietly for the same period. Conditions will be counterbalanced. At both visits cardiovascular responses (heart rate, blood pressure, and heart rate variability) will be assessed as measures of autonomic activation before, during and after the task period. Participants will also have an intravenous catheter inserted and blood drawn at ten time points over the two hour testing period on each occasion. Blood samples will be sent to laboratories at the University of Pittsburgh and at Columbia University for the assessment of mitochondria-derived signalling molecules, inflammatory markers, and cortisol levels.
There are around 1 million young adult cancer survivors in the United States. Young adult cancer survivors are an underserved and vulnerable subgroup of survivors that experience increased risk for chronic health conditions like cardiovascular disease, metabolic syndrome, secondary cancers, premature aging, and premature death. Modifiable lifestyle factors contribute to and compound risks for late and long-term health effects from cancer and its treatment, making them high-impact targets for behavioral interventions. International consensus guidelines recommend cancer survivors of all ages be physically active, consume a healthy diet, and achieve and maintain a healthy weight. Fewer than half of young adult cancer survivors meet guideline recommendations for vegetable intake, physical activity and the majority self-report having an overweight/obese BMI. To date, there are few physical activity interventions, and no nutritional interventions designed specifically for young adult cancer survivors. Digital behavior change interventions have emerged as feasible and efficacious approaches to reach and address unmet needs among young adult cancer survivors as they overcome barriers of time, flexibility, affordability, and access. Reaching these populations has been facilitated by digital tools like wearable devices that enable real-time data capture to guide the provision of individualized feedback and tailored goal setting based on personal progress. This pilot trial will use the Multiphase Optimization Strategy (MOST), an engineering-inspired framework, and a highly efficient experimental design to evaluate the feasibility of 4 intervention components to improve physical activity and nutrition behaviors among young adult cancer survivors. Young adult cancer survivors (n=80), diagnosed between ages 18-39, will be recruited to receive a core 3-month digital physical activity and nutrition intervention that includes evidence-based lessons and behavioral skills training with an emphasis on adherence to American Cancer Society (ACS) guidelines for cancer survivors and self-monitoring of physical activity and dietary behaviors. Additionally, participants will be randomized to four intervention components--each with two levels-- including: 1) simplified dietary tracking (daily tracking of green (low-calorie, high nutrients) vs. red (high-calorie, high-fat, low nutrients) foods), 2) dietary goals using simplified approach (daily goals vs. no goals), 3) supportive text messages (yes vs. no), 4) lesson delivery (all provided once vs. weekly). Assessments of outcomes will be conducted at baseline, 6 weeks, and 3 months to accomplish the following specific aims: 1) Evaluate the feasibility and acceptability the intervention at 3 months; 2) Evaluate intervention effects on change in physical activity and diet quality; 3) Evaluate intervention effects on secondary outcomes at 6 weeks and 3 months; and 4) Explore whether theoretical constructs (perceived competence, self-regulation, self-efficacy, and perceived relatedness) mediated the effects of the intervention on change in health behaviors at 3 months.
Rosemary is an herb exhibits biological properties, attenuates inflammation, oxidative stress, and improves lipid profile. Here, we evaluated the effects of rosemary aqueous extract (RE) on mice fed with a high-fat diet (HFD). Male C57BL/6 mice were administered a control diet or HFD for 10 weeks. The treated groups received RE in the diet at different concentrations: 25, 250, and 500 mg/100 g. After 10 weeks, serum concentrations of glucose, lipid, insulin, leptin, adiponectin, and cytokines were evaluated and the oxygen radical absorbance capacity was determined. Histological analysis was performed to determine the concentrations of triacylglycerides (TG), total cholesterol, cytokines, and antioxidant enzymes as well as the expression of genes involved in lipid metabolism, oxidative stress, and inflammation. The dietary RE ameliorated HFD-induced weight gain, adipose tissue weight, glucose intolerance, and insulin, leptin, and free fatty acid levels. Reduction in hepatic TG deposition was observed. The levels of inflammatory cytokines decreased, and the expression of genes involved in lipid metabolism increased. RE mitigated oxidative stress and reduced the production of reactive oxygen species in HepG2 and 3T3-L1 cells. Therefore, RE is a potential therapeutic agent for the prevention of inflammation and oxidative stress outcomes associated with obesity.
FIELD: organic chemistry, heterocyclic compounds, medicine, pharmacy. SUBSTANCE: invention relates to novel thienopyrimidines of the general formula (I)   or their physiologically acceptable salts comprising properties of inhibitors of activity of phosphodiesterase V. These compounds can be used in pharmaceutical industry for treatment of patients with cardiovascular diseases, in part, cardiac insufficiency and for therapy of potency disorder. In compounds of the general formula (I) R 1  and R 2  mean independently each of other H, A or Hal being one of residue R 1  or R 2  does not mean H; R 1  and R 2  mean in common also alkylene with 3-5 carbon atoms; R 3  and R 4  mean independently each of other H, OA or Hal; R 3  and R 4  mean in common also -O-CH 2 -O- or -O-CH 2 -CH 2 -O-; A means alkyl with 1-6 carbon atoms; X means 1-imidazolyl, 2-methyl-imidazolyl, pyrazolyl, 1,2,4-triazolyl-1-yl or 3-pyridyl; Hal means F, Cl, Br or J atoms; n = 1 under condition that if R 1  and R 2  mean H, A or Hal independently each of other being one of residue R 1  and R 2  does not mean H always then R 3  and R 4  do not mean in common H. Invention relates also to method of synthesis of compound of the formula (I) where X is bound through N-atom involves interaction of compound of the formula (II)   with imidazole, 2-methylimidazole, pyrazole, 1,2,4-triazole or in the case of synthesis of compounds where X is bound through C-atom by interaction of compound of the formula (III)   with compound of the formula (IV)   where L means Cl, Br, OH, SCH 3  or reactive esterified OH-group; R 1 -R 4  and n have values indicated above with the following if necessary treatment of synthesized base with acid to obtain physiologically acceptable salt. Invention relates also to pharmaceutical composition comprising at least one of the above- mentioned compounds as suitable form for dosing and method of composition preparing. EFFECT: improved method of synthesis, valuable medicinal properties of compounds. 8 cl, 1 tbl, 16 ex
Men are inevitably plagued by prostate disease throughout their lives. However, the understanding of the pathogenesis of prostate diseases is still limited. In the 1960s, McNeal proposed the theory of prostate zones: the prostate was divided into three main zones: transition zone, central zone, and peripheral zone. Over the past 50 years, significant differences between different prostate zones have been gradually revealed. We summarized the most significant differences in different zones of the prostate. For the first time, we proposed the "apparent difference in prostate zones" concept. This new concept has been proposed to understand the different zones of the prostate better. It also provided new ideas for exploring the susceptibility of lesions in different prostate zones. Despite the reported differences between zones, the treatment of prostate-related diseases remains partition agnostic. Therefore, we also discussed the clinical significance of the "apparent difference in the prostate zone" and emphasized the necessity of prostate zones.
The following adverse reactions have been identified during post-approval use of Cefepime for Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In addition to the adverse reactions reported during the North American clinical trials with cefepime, the following adverse reactions have been reported during worldwide postmarketing experience. Encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia, myoclonus, seizures, and nonconvulsive status epilepticus have been reported. [see Warnings and Precautions (5.2)].

Anaphylaxis including anaphylactic shock, transient leukopenia, neutropenia, agranulocytosis and thrombocytopenia, have been reported.
An approach is disclosed for a method, a system, and a computer program product for storing information tailored to a user and a condition to be accessed offline on a local device. The information is retrieved from a set of online sources. The retrieved information is tailored according to a criteria and the condition to form a curated data. The curated data is on the local device. An index is provided to access a selected portion of the curated data. The index is used to answer queries from the user. Responsive to identifying a question without an answer identified in the retrieved content, searching for the answer when the device is online. Responsive to finding the answer online, updating the curated data stored on the local device.
Thermoplastic elastomeric polypropylene blends and a partially cross-linked ethylene-vinyl acetate copolymer. The mixtures of polyprolin and ethylene-vinyl acetate copolymers. Polypropylene blends and non-crosslinked ethylene-vinyl acetate copolymers have unsatisfactory elastic properties, for example, with respect to permanent elongation and impact strength in notched work. It has been found that by using ethylene-vinyl acetate copolymers partially crosslinked with gel contents of 3-50% by weight in admixture with isotactic polypropylene, improvements in the elastic properties are achieved, especially in the impact resistance in the piece. Notched and in the permanent elongation, with respect to the comparative mixtures with non-crosslinked ethylene-vinyl acetate copolymers. (Machine-translation by Google Translate, not legally binding)
In the surgery group, a padded dorsal above elbow splint is applied in ED. Reduction and percutaneous pinning are performed under anesthesia in operating room by an experienced attending pediatric orthopedic surgeon within 7 days from the injury. Pin fixation is performed with two 1.6 mm pins. Padded dorsal above elbow and volar below elbow splints are applied. Splints and pins are removed at the outpatient clinic at 4 weeks after surgery.
PURPOSE: To assess, in a large population of Adult Spinal Deformity (ASD) patients, the true interest of varying the upper anchors as a protective measure against Proximal Junctional Kyphosis (PJK), by analyzing and comparing 2 groups of patients defined according to their proximal construct. Another objective of the study is to look for any other factors, radiological or clinical, that would affect the occurrence of the proximal failure.
METHODS: Retrospective review of a prospective ASD database collected from 5 centers. Inclusion criteria were age of at least 18 years, presence of a spinal deformity with instrumentation from T12 or above to the pelvis, with minimum 2 years of follow-up. Demographic data, spinopelvic parameters, functional outcomes and complications were collected. Multiple logistic regression analysis was performed to identify the risk factors that would affect the occurrence of PJK.
RESULTS: 254 patients were included. 166 in the group "screws proximally" (SP) and 88 in the group "hooks proximally" (HP). There was no difference between both groups for PJK (p = 0.967). The occurrence of PJK was rather associated with greater age and BMI, higher preoperative kyphosis, worst preoperative SRS22 and SF36 scores, greater postoperative Sagittal Vertical Axis (SVA), coronal malalignment and kyphosis.
CONCLUSION: The use of proximal hooks was not effective to prevent PJK after ASD surgery, when compared to proximal screws. Worse preoperative functional outcomes and worse postoperative sagittal and also coronal malalignment were the main drivers for the occurrence of PJK regardless the type of proximal implant.
BACKGROUND: Foot pain has been associated to factors like: fat, body mass index, age increased, female gender and the presence of pathologies. Although evidence is limited. The purpose is to determine the predictive factors for foot pain in the adult population.
METHODS: From January to December 2021, 457 patients were > 18 years, gave signed informed consent to take part to this cross sectional study. All completed demographic data and various questionnaires related to pain: Foot Function Index, EuroQoL-5D and Visual Analogue Scale (foot pain). Anthropometric measurements were obtained using McPoil platform and foot posture was assessed by the Foot Posture Index (FPI). To determine whether a volume change is a predictive factor for foot pain, a parameter was established: the volumetric index for footwear (VIF). Factors linked to the presence of pain, including the considered VIF variables, were analyzed through multivariable logistic regression.
RESULTS: Among the study population, 40.7% were male and 59.3% female. The mean age of 39.06 years and a body mass index of 25.58 Kg/cm2. The logistic regression model had a classification capability of 72.4%, a sensitivity of 72.3% and a specificity of 73%, in which, the predictors considered were the variables found to have a significant association with FFI-pain > 45 points,, showed that younger women, with a higher BMI, higher values of right FPI (pronation), poorer overall perceived health and with problems in walking were more likely to experience foot pain.
CONCLUSION: Predictive factors for foot pain in the adult population include gender, age, Body Mass Index, FPI on the right foot, perceived health and mobility. Clinical implication, the presented measure aids physicians in assessing their patients´ foot pain likelihood.
[PROBLEMS] To provide a methioninase inhibitor, which inhibits methioninase of a bacterial origin to thereby regulate the production of a malodorant substance mercaptan, and a composition and a food or a drink containing the same. [MEANS FOR SOLVING PROBLEMS] A methioninase inhibitor, which contains as the active ingredient an extract obtained from a plant of the genus Myrsine of the family Myrsinaceae (preferably Myrsine Seguinii Lev.), and a composition and a food or a drink containing the same. A methioninase inhibitor, which contains as the active ingredient one or more members selected from the group consisting of myrsinoic acid A, myrsinoic acid B, myrsinoic acid C, myrsinoic acid E and myrsinoic acid F, and a composition and a food or a drink containing the same. Preferably, a methioninase inhibitor, in which myrsinoic acid A, myrsinoic acid B, myrsinoic acid C, myrsinoic acid E and myrsinoic acid F are obtained from a plant of the genus Myrsine of the family Myrsinaceae (preferably Myrsine Seguinii Lev.), and a composition and a food or a drink containing the same.
The present invention discloses outer application liquid for treating psoriasis, which is composed of the components of the following portions by weight: 82 portions of raw ephedra tincture with the concentration of 25 to 30%, 3.5 to 7.5 portions of urea, 3.6 to 6.51 portions of sodium hydroxide, 1.5 to 3.8 portions of anaesthetic with stable alkalinity and 2.7 to 8.1 portions of potassium iodide. The outer application liquid for treating psoriasis sterilizes, softens hard masses by moxibustion, absorbs clots, removes stasis, removes toxic substances and eliminates evil, the outer application liquid for treating psoriasis can cause the abnormal state of normal psoriasis to be restored to a healthy state, the effective rate of the outer application liquid for treating normal psoriasis is 100%, and the healing rate of the outer application liquid for treating normal psoriasis is also 100%. The outer application liquid for treating psoriasis can radically heal normal psoriasis, and a patient has no recurrence for 2 to 5 years after recovery. After the outer application liquid for treating psoriasis heals psoriasis, the patient feels good and has smooth and clean skin similar to normal skin after the recovery, and no spot is left. When the medicine of the present invention is used for outer application, the medicine has no toxic and side effect on the whole body except local stimulation in the coating process of the medicine, and the use of the medicine does not need dietary contraindication. The outer application liquid for treating psoriasis has low cost and relieves the economic burden of a patient.
Maternal obesity in pregnancy is strongly associated with complications such as fetal overgrowth and infants of obese mothers have an increased risk to develop obesity, diabetes, and cardiovascular disease later in life. However, the underlying mechanisms are not well established. Circulating levels of adiponectin are low in obese pregnant women and maternal circulating adiponectin is negatively associated with birth weight. We have reported that normalizing maternal adiponectin in obese pregnant mice prevents placental dysfunction, fetal overgrowth, and programming of offspring cardio-metabolic disease. However, the mechanistic link between maternal adiponectin, placental function, and fetal growth remains to be established. We hypothesized that trophoblast-specific overexpression of the adiponectin receptor 2 (Adipor2) in healthy pregnant mice inhibits placental mTORC1 signaling and nutrient transport, resulting in fetal growth restriction. Using lentiviral transduction of blastocysts with a mammalian gene expression lentiviral vector for up-regulation of Adipor2 (Adipor2-OX), we achieved a ~ 3-fold increase in placenta Adipor2 mRNA levels and a 2-fold increase of the ADIPOR2 protein in the trophoblast plasma membrane. Placenta-specific Adipor2-OX increased placental peroxisome proliferator-activated receptor-α phosphorylation, ceramide synthase expression and ceramide concentrations. Furthermore, Adipor2-OX inhibited placental mTORC1 signaling and reduced in vivo placental transport of glucose and amino acids. Lastly, Adipor2-OX reduced fetal weight by 11%. These data provide mechanistic evidence that placental Adipor2 signaling directly affects fetal growth. We propose that low circulating adiponectin in maternal obesity causes fetal overgrowth and programs the offspring for cardio-metabolic disease mediated by a direct effect on placental function.
1. Controlled release pharmaceutical preparation in the form of doses, i.e. tablets or capsules which contains multi-particles of the size between 0.1-3.0 mm, and which contains an active component included in the matrix of pharmaceutically permissible adjuvants. Characterized in that: the active component is tramadol or its pharmaceutically permissible salt, where a dose contains from 50 mg to 800 mg of tramadol (per tramadol hydrochloride), and the matrix is a hydrophobic fusible carrier selected from among the following substances: hydrogenated vegetable oil, particularly castor oil, microcrystalline wax, beeswax, carnauba wax, glyceryl monostearate; possibly with the addition of a release modifying agent selected from among the following substances: polyethylene glycol, dicalcium phosphate or lactose, where the total amount of the active component in the preparation is between 10 and 90 percent by weight. 4. A method of producing controlled release pharmaceutical preparation in the form of doses, i.e. tablets or capsules, whereby the mixture of the active component and particles of a hydrophobic fusible carrier is placed in a known high-speed agitator and the mixture is processed. Characterized in that: Tramadol or its pharmaceutically permissible salt in the form of particles and a hydrophobic fusible carrier in the form of particles, which is selected from among the following substances: hydrogenated vegetable oil, particularly castor oil, microcrystalline wax, beeswax, carnauba wax, glyceryl monostearate, are applied, and possibly a release-modifying agent, selected from among the following substances: polyethylene glycol, dicalcium phosphate or lactose, is added to the mixture, where the total amount of the active component in the preparation is between 10 and 90 percent by weight and from 50 gm to 800 gm of the active component per each dose. During the processing in the high-speed agitator, such speed and energy is applied, by means of a heating jacket or microwave radiation, so that the temperature of the bed is at least 40 degrees C, the mixture is melted or softened and agglomerates with a cohesive granular structure and irregular shape and appearance, are obtained; further the agglomerates are broken into a mixture of a powder and small particles, and next the mixture is further processed in the high-speed agitator until particles sized from 0.1 to 0.3 mm are obtained; such particles are further used to fill capsules according to a known method, or are pressed to form tablets.